Skip to search formSkip to main contentSkip to account menu

ixazomib

Known as: {(1R)-1-[(2,5-dichlorobenzamido)acetamido]-3-methylbutyl}boronic Acid 
An active metabolite of MLN9708, a second generation, boron containing peptide proteasome inhibitor (PI) with potential antineoplastic activity… 
National Institutes of Health

Related topics

Related topics

15 relations

Broader (4)

Antineoplastic AgentsBoron CompoundsGlycineProtease Inhibitors

Narrower (3)

MLN 9708MLN2238ixazomib citrate
NCIt Antineoplastic Agent TerminologyPositive Regulation of ApoptosisProteasome Function InhibitionProteasome Inhibitors [MoA]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance
Triplet combinations containing a proteasome inhibitor are a standard of care in newly diagnosed multiple myeloma (NDMM). We… 
Review
2019
Review
2019
Boronic acids as building blocks for the construction of therapeutically useful bioconjugates.
Bioconjugates are multifunctional constructs in which biomolecules like peptides, proteins, vitamins and nucleic acids are… 
Review
2018
Review
2018
Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor
Ixazomib, the first oral proteasome inhibitor, is approved in combination with lenalidomide and dexamethasone for the treatment… 
Review
2017
Review
2017
Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies.
Review
2017
Review
2017
Posttransplant maintenance therapy in multiple myeloma: the changing landscape
Transplant-eligible patients with multiple myeloma (MM) now have extended survival after diagnosis owing to effective modern… 
Review
2016
Review
2016
Ixazomib: First Global Approval
Ixazomib (Ninlaro®) is an orally bioavailable, reversible proteasome inhibitor developed by Millennium Pharmaceuticals, Inc. (now… 
Review
2015
Review
2015
Ixazomib for the treatment of multiple myeloma
Introduction: Proteasome inhibition is a mainstay in the treatment of multiple myeloma (MM). Bortezomib, the first proteasome… 
2015
2015
Safety and efficacy of carfilzomib (CFZ) in previously-treated systemic light-chain (AL) amyloidosis
Review
2014
Review
2014
Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.
Over the past ten years, proteasome inhibition has emerged as an effective therapeutic strategy for treating multiple myeloma (MM… 
Review
2005
Review
2005
Stem cell transplantation in multiple myeloma
Single autologous transplantation High-dose treatment (HDT) with autologous stem cell transplantation (ASCT) has been shown to… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)